Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2010

01.11.2010 | 2010 SSAT Plenary Presentation

Redefining Mortality After Pancreatic Cancer Resection

verfasst von: James Edward Carroll, Jillian K. Smith, Jessica P. Simons, Melissa M. Murphy, Sing Chau Ng, Shimul A. Shah, Zheng Zhou, Jennifer F. Tseng

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Distinct outcome measures such as in-hospital and 30-day mortality have been used to evaluate pancreatectomy results. We posited that these measures could be compared using national data, providing more precision for evaluating published outcomes after pancreatectomy.

Methods

Patients undergoing resection for pancreatic cancer were identified from the linked SEER-Medicare databases (1991–2002). Mortality was analyzed and trend tests were utilized to evaluate risk of death within ≤60 days of resection and from 60 days to 2 years post-resection. Univariate analysis assessed patient characteristics such as race, gender, marital status, socioeconomic status, hospital teaching status, and complications.

Results

One thousand eight hundred forty-seven resected patients were identified: 7.7% (n = 142) died within the first 30 days, 83.6% of whom died during the same hospitalization. Postoperative in-hospital mortality was 8.1% (n = 150), 79% of which was within 30 days, greater than 90% of which was within 60 days. Risk of death decreased significantly over the first 60 days (P < 0.0001). After 60 days, the risk did not decrease through 2 years (P = 0.8533). Univariate analysis showed no difference between the two groups in terms of race, gender, marital status, and socioeconomic status, but patients dying within 60 days were more likely to have experienced a complication (41.1% vs. 17.0%, P < 0.0001).

Conclusions

In-hospital and 30-day mortality after resection for cancer are similar nationally; thus, comparing mortality utilizing these measures is acceptable. After a 60-day post-resection window of increased mortality, mortality risk then continues at a constant rate over 2 years, suggesting that mortality after pancreatectomy is not limited to early (“complication”) and late (“cancer”) phases. Determining ways to decrease perioperative mortality in the 60-day interval will be critical to improving overall survival.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.CrossRefPubMed Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–49.CrossRefPubMed
2.
Zurück zum Zitat Michalski CW, Weitz J, Buchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 2007;4:526–35.CrossRefPubMed Michalski CW, Weitz J, Buchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 2007;4:526–35.CrossRefPubMed
3.
Zurück zum Zitat McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007;246:246–53.CrossRefPubMed McPhee JT, Hill JS, Whalen GF, et al. Perioperative mortality for pancreatectomy: a national perspective. Ann Surg 2007;246:246–53.CrossRefPubMed
4.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173–80.CrossRefPubMed Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173–80.CrossRefPubMed
5.
Zurück zum Zitat Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 1995;181:483–503.PubMed Gudjonsson B. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. J Am Coll Surg 1995;181:483–503.PubMed
6.
Zurück zum Zitat Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996;223:718–25; discussion 25–8CrossRefPubMed Lillemoe KD, Cameron JL, Yeo CJ, et al. Pancreaticoduodenectomy. Does it have a role in the palliation of pancreatic cancer? Ann Surg 1996;223:718–25; discussion 25–8CrossRefPubMed
7.
Zurück zum Zitat Bradley EL, 3 rd. Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas 2008;37:349–51.CrossRefPubMed Bradley EL, 3 rd. Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas 2008;37:349–51.CrossRefPubMed
8.
Zurück zum Zitat Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008;247:456–62.CrossRefPubMed Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008;247:456–62.CrossRefPubMed
9.
Zurück zum Zitat Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005;242:326–41; discussion 41–3PubMed Khuri SF, Henderson WG, DePalma RG, Mosca C, Healey NA, Kumbhani DJ. Determinants of long-term survival after major surgery and the adverse effect of postoperative complications. Ann Surg 2005;242:326–41; discussion 41–3PubMed
11.
Zurück zum Zitat International Classification of Diseases, 9th Revision, Clinical Modification. Salt Lake City: Medicode Publications; 2001. International Classification of Diseases, 9th Revision, Clinical Modification. Salt Lake City: Medicode Publications; 2001.
12.
Zurück zum Zitat Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–67.CrossRefPubMed Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258–67.CrossRefPubMed
13.
Zurück zum Zitat Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.CrossRefPubMed Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613–9.CrossRefPubMed
14.
Zurück zum Zitat Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable cancer?: a population-based assessment of US practices. Cancer;116:1681–90 Simons JP, Ng SC, McDade TP, Zhou Z, Earle CC, Tseng JF. Progress for resectable cancer?: a population-based assessment of US practices. Cancer;116:1681–90
15.
Zurück zum Zitat Murphy MM, Simons JP, Ng SC, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:2968–77.CrossRefPubMed Murphy MM, Simons JP, Ng SC, et al. Racial differences in cancer specialist consultation, treatment, and outcomes for locoregional pancreatic adenocarcinoma. Ann Surg Oncol 2009;16:2968–77.CrossRefPubMed
16.
Zurück zum Zitat Brennan MF, Radzyner M, Rubin DM. Outcome—more than just operative mortality. J Surg Oncol 2009;99:470–7.CrossRefPubMed Brennan MF, Radzyner M, Rubin DM. Outcome—more than just operative mortality. J Surg Oncol 2009;99:470–7.CrossRefPubMed
17.
Zurück zum Zitat Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008;12:701–6.CrossRefPubMed Ferrone CR, Brennan MF, Gonen M, et al. Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 2008;12:701–6.CrossRefPubMed
18.
Zurück zum Zitat Reddy DM, Townsend CM, Jr., Kuo YF, Freeman JL, Goodwin JS, Riall TS. Readmission after pancreatectomy for pancreatic cancer in medicare patients. J Gastrointest Surg 2009;13:1963–74; discussion 74–5CrossRefPubMed Reddy DM, Townsend CM, Jr., Kuo YF, Freeman JL, Goodwin JS, Riall TS. Readmission after pancreatectomy for pancreatic cancer in medicare patients. J Gastrointest Surg 2009;13:1963–74; discussion 74–5CrossRefPubMed
Metadaten
Titel
Redefining Mortality After Pancreatic Cancer Resection
verfasst von
James Edward Carroll
Jillian K. Smith
Jessica P. Simons
Melissa M. Murphy
Sing Chau Ng
Shimul A. Shah
Zheng Zhou
Jennifer F. Tseng
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2010
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-010-1326-4

Weitere Artikel der Ausgabe 11/2010

Journal of Gastrointestinal Surgery 11/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.